{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(2)"],"submitter":["Moravej H"],"pubmed_abstract":["<h4>Background</h4>Limited durability of clinical responses remains a major challenge in chimeric antigen receptor (CAR)-T therapy. CAR-enhancers (CAR-Es), which fuse tumor antigens to interleukin (IL)-2 muteins, provide a targeted strategy to enhance CAR-T persistence and function. It remained unclear whether CAR-Es are effective across distinct tumor contexts, when using patient-derived T cells, or in preventing exhaustion and sustaining persistence. It was also unknown whether CAR-Es can selectively expand CAR-Ts in humanized mice with pre-existing T cells, and to what extent their efficacy depends on IL-2Rβγ vs IL-2Rα engagement. While IL-2Rα (CD25) has been classically linked to potent antitumor responses and memory formation, it also drives IL-2-associated toxicities, including vascu"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e013665"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12918668"],"repository":["biostudies-literature"],"pubmed_title":["Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα."],"pmcid":["PMC12918668"],"pubmed_authors":["Moravej H","Rivet VM","Nia HT","Fulciniti M","Kowalewski A","Nadeem O","Berland L","Mantri SR","Munshi NC","Khan RMM","Jacobson CA","Baral J","Marcandalli E","Munaretto LA","Lee UJ","Wolff AN","Gabr Z","Taklifi P","Sperling AS","Hemann M","Allen HH","Nili A","Farkash Z","Mercadante D","Louis BBV","Rashidian M","Rakhshandehroo T","Regan K"],"additional_accession":[]},"is_claimable":false,"name":"Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.","description":"<h4>Background</h4>Limited durability of clinical responses remains a major challenge in chimeric antigen receptor (CAR)-T therapy. CAR-enhancers (CAR-Es), which fuse tumor antigens to interleukin (IL)-2 muteins, provide a targeted strategy to enhance CAR-T persistence and function. It remained unclear whether CAR-Es are effective across distinct tumor contexts, when using patient-derived T cells, or in preventing exhaustion and sustaining persistence. It was also unknown whether CAR-Es can selectively expand CAR-Ts in humanized mice with pre-existing T cells, and to what extent their efficacy depends on IL-2Rβγ vs IL-2Rα engagement. While IL-2Rα (CD25) has been classically linked to potent antitumor responses and memory formation, it also drives IL-2-associated toxicities, including vascu","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T09:17:29.707Z","creation":"2026-07-09T10:46:51.594Z"},"accession":"S-EPMC12918668","cross_references":{"pubmed":["41708145"],"doi":["10.1136/jitc-2025-013665"]}}